Secondary Logo

Journal Logo

Correspondence

A case–control study of virological and immunological effects of highly active antiretroviral therapy in HIV-infected patients with advanced age

Manfredi, Roberto; Chiodo, Francesco

Author Information

The mean age at first diagnosis of HIV infection is progressively increasing worldwide [1–5] (with 1–2% of cases of HIV infection occurring in persons aged 65 years or older) [1,4], but very limited data have been available until now about the efficacy of highly active antiretroviral therapy (HAART) according to the patients' age [6–11].

The virological and immunological response to a first-line HAART containing two nucleoside analogues and a potent protease inhibitor evaluated in 21 consecutive patients 55 years of age or older, was retrospectively compared with that of 84 individuals randomly selected from nearly 450 patients aged 35 years or less who had started a similar HAART regimen since 1997, in a case–control study including a 12 month follow-up. Ultrasensitive assays were used for quantitative viral load measurement: the branched DNA method and the nucleic acid sequence-based assay, with minimum detectable levels of 50 and 40 copies/ml, respectively. The adherence to HAART was checked by monthly visits, including direct distribution of antiretroviral compounds, and drug accountability.

The two patient groups were comparable with regard to sex, number of individuals naive to antiretroviral agents, duration of previous anti-HIV therapy in experienced patients, expected potency of selected HAART regimen (containing either indinavir, ritonavir, or nelfinavir), levels of compliance with administered compounds, drug-related adverse events (mild to moderate in severity, and never affecting the continuation of HAART), as well as the baseline mean plasma viral load and mean CD4 lymphocyte count (Table 1).

Table 1
Table 1:
Outcome of first-line highly active antiretroviral therapy in 21 consecutive HIV-infected patients aged 55 years or older, compared with that of 84 control subjects aged 35 years or less.

Compared with patients aged 35 years or less, those aged 55 years or older showed a greater prevalence of sexually transmitted disease, a more frequent diagnosis of AIDS, a significantly reduced decrease of viraemia at the sixth month of follow-up, although a similar virological response was attained in both patient groups after 12 months (−1.8 and −1.9 log10, respectively), with a comparable number of patients reaching complete viral suppression. On the other hand, the immunological response was significantly less favourable in older compared with younger patients, after 6 and especially 12 months of follow-up, and individuals with a modest CD4 cell count gain were significantly more frequent in the older as opposed to the younger group.

Before the HAART era, the elderly were known to have a more severe HIV disease evolution and a shorter survival rate [12–21] : in 1995, older age was related linearly to an increased probability of death, and a relative risk of progression to AIDS or death of 2% per year of age was estimated [15]. Patients' age showed a marked influence on the progression to stage C disease [17], proved independently related to the decline of CD4 cell count in untreated patients [19], and recently showed a correlation with plasma viraemia [22]. The inability of older individuals to replace impaired immune defences is expected to play a key pathogenic role [16,18]. However, a recent study [5] identified access to antiretroviral therapy as the only predictor of survival in a cohort of 86 patients aged 50 years or older. Recently, some large literature series that evaluated predictors of HAART outcome [6,9–11], failed to identify age as a relevant variable: the latter study [11] even excluded age as a determinant for naive T cell repopulation, independently from virological outcome. No difference [7], or a slightly increased risk [8] of clinical failure of HAART, were detected in an Italian setting, in patients aged over versus those aged less than 35 and 34 years, respectively [7,8].

In our experience, older age does not seem to affect significantly the long-term virological outcome of HIV disease initially treated with HAART (despite an apparently less rapid drop of plasma viral load levels), but the immunological response (as assessed by the profile of recovery of the peripheral CD4 cell count), appears to be significantly blunted among patients aged 55 years or over (independently from a series of clinical and therapeutic variables). A limited residual function of the thymus and other lymphoid tissues [23,24], and a consequently reduced potential for immune reconstitution [22,25] (which appears somewhat related to a recovery of thymic output) [22,23,26,27] may play an important role, although the central position of the thymus in immune restoration after HAART is actively discussed [22,26]. An aggressive therapeutic approach is therefore warranted for older patients with HIV disease, with special attention paid to the administration of potent antiretroviral compounds, and the continuation of appropriate primary or secondary chemoprophylactic regimens for opportunistic infections (when indicated), waiting for the availability of novel immunotherapeutic strategies, which would possibly ensure a more rapid and effective recovery of the immune defences, when advanced age is of concern.

Roberto Manfredi

Francesco Chiodo

References

1. Hinkle KL. A literature review: HIV seropositivity in the elderly. J Gerontol Nurs 1991, 17: 12 –17.
2. El Sadr W, Gettler J. Unrecognized human immunodeficiency virus infection in the elderly. Arch Intern Med 1994, 155: 184 –186.
3. Woolery WA. Occult HIV infection: diagnosis and treatment of older patients. Geriatrics 1997, 52: 51 –61.
4. Bachus MA. HIV and the older adult. J Gerontol Nurs 1998, 24: 41 –46.
5. Keller MJ, Hausdorff JM, Kyne L, Wei JY. Is age a negative prognostic indicator in HIV infection or AIDS? Aging 1999, 11: 35 –38.
6. Casado JL, Perez-Elías MJ, Antela A. et al. Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients. AIDS 1998, 12: F131 –F135.
7. D'Arminio Monforte A, Testa L, Adorni F. et al. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection. AIDS 1998, 12: 1631 –1637.
8. D'Arminio Monforte A, Testori V, Adorni F. et al. CD4 cell counts at the third month of HAART may predict clinical failure. AIDS 1999, 13: 1669 –1676.
9. Wit FWNM, Van Leeuwen R, Weverling GJ. et al. Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency type 1-infected persons. J Infect Dis 1999, 179: 790 –798.
10. Ledergerber B, Egger M, Opravil M. et al. Clinical progression and virological failure of highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999, 353: 863 –868.
11. Pakker NG, Kroon EDMB, Roos MTL. et al. Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. AIDS 1999, 13: 203 –212.
12. Bacchetti P, Osmond D, Chaisson RE. et al. Survival patterns in the first 500 patients with AIDS in San Francisco. J Infect Dis 1988, 157: 1044 –1047.
13. Lemp GF, Hirozawa AM, Cohen JB, Derish PA, McKinney KC, Hernandez SR. Survival for women and men with AIDS. J Infect Dis 1992, 166: 74 –79.
14. Operskalski EA, Stram DO, Lee H. et al. Human immunodeficiency virus type 1 infection: relaype 1 infection: relaype 1 infection: relationship of risk group and age to rate of progression to AIDS. J Infect Dis 1995, 172: 648 –655.
15. Chaisson RE, Keruly JC, Moore RD. Race, sex, drug use, and progression of human immunodeficiency virus disease. N Engl J Med 1995, 333: 751 –756.
16. Adler WH, Baskar PV, Chrest FJ, Dorsey-Cooper B, Winchurch RA, Nagel JE. HIV infection and aging: mechanisms to explain the accelerated rate of progression in the older patient. Mech Ageing Dev 1997, 96: 137 –155.
17. Belanger F, Meyer L, Carre N, Coutellier A, Deveau C. Influence of age at infection on human immunodeficiency virus disease progression to different clinical endpoints: the SEROCO cohort (1988–1994). Int J Epidemiol 1997, 26: 1340 –1345.
18. Operskalski EA, Mosley JW, Busch MP, Stram DO. Influences of age, viral load, and CD4+ count on the rate of progression of HIV-1 infection to AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 15: 243 –244.
19. Soriano V, Castilla J, Gomez-Cano M. et al. The decline in CD4+ T lymphocytes as a function of the duration of HIV infection, age at seroconversion, and viral load. J Infect 1998, 36: 307 –311.
20. Alioum A, Leroy V, Commenges D, Dabis F, Salamon R. Effect of gender, age, transmission category, and antiretroviral therapy on the progression of human immunodeficiency virus infection using multistate Markov models. Epidemiology 1998, 9: 605 –612.
21. Rezza G. Determinants of progression to AIDS in HIV-infected individuals: an update from the Italian Seroconversion Study. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 17 (Suppl. 1) : S13 –S16.
22. Haynes BF, Hale LP, Weinhold KJ. et al. Analysis of the adult thymus in reconstitution of T lymphocytes in HIV-1 infection. J Clin Invest 1999, 103: 453 –460.
23. Douek DC, McFarland RD, Keiser PH. et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998, 396: 690 –695.
24. Beltz L. Thymic involution and HIV progression. Immunol Today 1999, 20: 429. 429.
25. Poulin JF, Sékaly RP. Function of the thymus in HIV-infected adults. JAMA 1999, 282: 219. 219.
26. Zhang L, Lewin SR, Markowitz M. et al. Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy. J Exp Med 1999, 190: 725 –732.
27. Smith KY, Valdez H, Landay A. et al. Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy. J Infect Dis 2000, 181: 141 –147.
© 2000 Lippincott Williams & Wilkins, Inc.